ALPG

ALPG Molekülinformation

Englischer Name	Alkaline phosphatase	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	3	Target-Alias	Alkaline Phosphatase
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Alkaline phosphatase
Target-Alias	Alkaline Phosphatase
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Approved

ALPG Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Mouse (1)Human (2)
Etikett
His Tag (2)His Tag & Avi Tag (1)
Marker
Unconjugated (2)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT ALG-H52H9	Human	HEK293	Human ALPG / ALPPL2 Protein, His Tag, low endotoxin (active enzyme, MALS verified)	In den Warenkorb legen
ALG-H52E1	Human	HEK293	Biotinylated Human ALPG / ALPPL2 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
ALG-M52H9	Mouse	HEK293	Mouse ALPG / ALPPL2 Protein, His Tag (active enzyme, MALS verified)	In den Warenkorb legen

Gesamtmenge3

Produktanfrage

ALPG Molekülhintergrund

ALPPL2 is specifically highly expressed in naïve pluripotent stem cells. Moreover, in naïve state somatic cell reprogramming, naïve-primed transformation and other systems, the use of the ALPPL2 promoter-driven fluorescent reporter system can specifically indicate the establishment or withdrawal of naïve state pluripotency, thereby identifying ALPPL2 as naïve state pluripotent. specific cell surface markers. Some studies have found that knockout of ALPPL2 can specifically affect the establishment, stability and maintenance of naïve state pluripotency, proving that ALPPL2 protein is a functional naïve state surface molecular marker.

ALPG Molekülalias

ALPG,GCAP,ALP-1,ALPPL2,PLAP-like,ALPPL,Alkaline phosphatase, germ cell type

Antikörperprojekt-Handelsplattform

Projektname	Projektphase	Molekültyp	Molekülquelle	Krankheitsgebiet	Indikationen
ALPP/ALPPL2 mAb - 01	PCC	Monoclonal	Humanized Mouse	Solid Tumor	Endometrial cancer,Ovarian cancer

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
ALXN-1850	ALXN-1850	Phase 3 Clinical	Alexion Pharmaceuticals Inc	Hypophosphatasia	Details
Amifostine for nasoduodenal delivery (Xerient Pharma)	XER-001	Phase 2 Clinical	Xerient Pharma	Pancreatic Neoplasms	Details
placenta-derived protein (Zoltan)	PALP	Clinical	Zoltan Laboratories	Cachexia; Diabetes Mellitus; Obesity	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Amifostine	WR-2721C; NSC-296961; YM-08310; S-8744; SAPEP; WR-2721	Approved	Medimmune Llc	Ethyol, 天地达, 安福定	Mainland China	Cytoprotective adjuvant	China Grand Automotive Services Group Co Ltd	1995-12-08	Acute Radiation Syndrome; Bone Marrow Diseases; Breast Neoplasms; Carcinoma; Cytoprotective adjuvant; Fanconi Anemia; Gestational Trophoblastic Disease; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Mucositis; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nasopharyngeal Neoplasms; Neurotoxicity Syndromes; Neutropenia; Ovarian Neoplasms; Peripheral Nervous System Diseases; Prostatic Neoplasms; Salivary Gland Diseases; Sarcoma; Solid tumours; Trigeminal Neuralgia	Details